Latest price of RET inhibitor Pralsetinib produced by CStone Pharmaceuticals

Pralsetinib is a RET inhibitor produced by CStone Pharmaceuticals and approved for marketing in China. It is mainly used to treat RET fusion-positive non-small cell lung cancer and some thyroid cancer patients. These patients had limited treatment options in the past, and the emergence of platinib has brought them new targeted treatment opportunities. The drug was launched in China in 2021. Due to its remarkable clinical effects, it has gradually attracted the attention of patients and doctors, but the price has always been the focus of many patients' concerns.

Currently in the Chinese market, the price of the original drug Platinib is relatively high. The common specifications are 100mg×120 capsules, and the price of a box is about 60,000 yuan. Since the drug has not yet been included in the national medical insurance list, most patients need to pay the full cost out of pocket. In order to reduce the financial pressure of medication, CStone Pharmaceuticals has teamed up with some public welfare funds to launch a drug donation assistance program, so that some eligible patients can receive donated drugs after purchasing a certain amount of drugs, thereby reducing the overall treatment cost.

In addition to the original drug, there are already multiple versions of platinib generic drugs in overseas markets, and the prices are more affordable. For example, a box of generic platinib produced by Lucius in India costs more than 3,000 yuan. The ingredients and efficacy of generic drugs are basically the same as those of the original drugs, providing a new option for patients with heavy financial burdens. However, when choosing generic drugs, patients need to purchase them through formal channels to ensure the safety and efficacy of the drugs.

It should be noted that the price of platinib will vary due to regional differences, sales channels and exchange rate fluctuations. When considering purchasing, patients should communicate with their attending doctor and choose a suitable version of the drug based on their own financial situation. At the same time, be sure to obtain medicines through regular hospital pharmacies or legal channels to avoid the risks of counterfeit or inferior medicines. For patients taking long-term medication, reasonable price planning and utilization of assistance programs are important guarantees to ensure continuity of treatment.

Reference materials:https://www.drugs.com/